Additionally, we showed that tumor-informed ddPCR is a feasible and reliable tool for evaluating KIT aberrations, including complex indels; hence, we propose that it could be implemented in future personalized oncology strategies, such as disease-response monitoring and minimal residual disease assessment in the adjuvant setting of AM and MM. Here, KIT is linked to Miyoshi myopathy.